For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenues | 0 | |||
| Selling, general and administrative | 154,024 | |||
| Total operating expenses | 154,024 | |||
| Loss from operations | -154,024 | |||
| Liability forgiveness | 62,032 | |||
| Interest expense - related parties | 9,154 | |||
| Total other expenses | 52,878 | |||
| Loss before income tax expense | -101,146 | |||
| Income tax expense | 0 | |||
| Net loss | -101,146 | |||
| Basic and diluted loss per share of common stock | 0 | |||
| Weighted average number of shares of common stock outstanding | 60,042,000 | |||
ACRO BIOMEDICAL CO., LTD. (ACBM)
ACRO BIOMEDICAL CO., LTD. (ACBM)